New Zealand - English - Medsafe (Medicines Safety Authority)

boucher & muir (nz) ltd t/a mercury pharma (nz) - tranylcypromine sulfate 13.68mg equivalent to 10 mg tranylcypromine; tranylcypromine sulfate 13.68mg equivalent to 10 mg tranylcypromine - film coated tablet - 10 mg - active: tranylcypromine sulfate 13.68mg equivalent to 10 mg tranylcypromine excipient: calcium sulfate carnauba wax red spectraspray acsl0673 erythrosine gelatin hypromellose magnesium stearate maize starch propylene glycol shellac sucrose active: tranylcypromine sulfate 13.68mg equivalent to 10 mg tranylcypromine excipient: calcium sulfate carnauba wax erythrosine gelatin magnesium stearate maize starch opadry red 06h250000 sucrose - parnate is indicated for the treatment of symptoms of depressive illness especially where treatment with other types of anti-depressants has failed. it is not recommended for use in mild depressive states resulting from temporary situational difficulties.

Israel - English - Ministry of Health

rafa laboratories ltd - morphine sulfate - tablets controlled release - morphine sulfate 30 mg - morphine - morphine - prolonged relief of severe pain.

Israel - English - Ministry of Health

rafa laboratories ltd - morphine sulfate - tablets controlled release - morphine sulfate 10 mg - morphine - morphine - prolonged relief of severe pain.

Israel - English - Ministry of Health

kamada ltd, israel - beclometasone dipropionate anhydrous; formoterol fumarate dihydrate - pressurised solution - formoterol fumarate dihydrate 6 mcg/dose; beclometasone dipropionate anhydrous 100 mcg/dose - formoterol and beclometasone - beclometasone - foster is indicated in the regular treatment of asthma where use of a combination product (inhaled corticosteroid and long-acting beta2-agonist) is appropriate:- patients not adequately controlled with inhaled corticosteroids and 'as needed' inhaled rapid-acting beta2-agonist or- patients already adequately controlled on both inhaled corticosteroids and long-acting beta2-agonists.copd :symptomatic treatment of patients with severe copd (fev1 < 50% predicted normal) and a history of repeated exacerbations, who have significant symptoms despite regular therapy with long-acting bronchodilators.

Israel - English - Ministry of Health

rafa laboratories ltd - fluticasone propionate; formoterol fumarate dihydrate - pressurised suspention for inhalation - fluticasone propionate 0.05 mg/dose; formoterol fumarate dihydrate 0.005 mg/dose - fluticasone - fluticasone - the regular treatment of asthma where use of a combination product (an inhaled corticosteroid and a long -acting β2 agonist) is appropriate:• for patients not adequately controlled with inhaled corticosteroids and ‘as required’ inhaled short -acting β2 agonist.• for patients already adequately controlled on both an inhaled corticosteroid and a long-acting β2 agonist.flutiform 50mcg/5mcg inhaler is indicated in adults, adolescents and children aged 5 years and above.

Israel - English - Ministry of Health

rafa laboratories ltd - fluticasone propionate; formoterol fumarate dihydrate - pressurised suspention for inhalation - fluticasone propionate 0.125 mg/dose; formoterol fumarate dihydrate 0.005 mg/dose - fluticasone - fluticasone - the regular treatment of asthma where use of a combination product (an inhaled corticosteroid and a long -acting β2 agonist) is appropriate:• for patients not adequately controlled with inhaled corticosteroids and ‘as required’ inhaled short -acting β2 agonist.• for patients already adequately controlled on both an inhaled corticosteroid and a long-acting β2 agonist.flutiform 125mcg/5mcg inhaler is indicated in adults and adolescents aged 12 years and above.

Israel - English - Ministry of Health

rafa laboratories ltd - fluticasone propionate; formoterol fumarate dihydrate - pressurised suspention for inhalation - fluticasone propionate 0.25 mg/dose; formoterol fumarate dihydrate 0.01 mg/dose - fluticasone - fluticasone - the regular treatment of asthma where use of a combination product (an inhaled corticosteroid and a long -acting β2 agonist) is appropriate:• for patients not adequately controlled with inhaled corticosteroids and ‘as required’ inhaled short -acting β2 agonist.• for patients already adequately controlled on both an inhaled corticosteroid and a long-acting β2 agonist.flutiform 250mcg/10mcg inhaler is indicated in adults only.

Ireland - English - HPRA (Health Products Regulatory Authority)

mundipharma pharmaceuticals limited - fluticasone propionate; formoterol fumarate dihydrate - pressurised inhalation, suspension - 125 µg/5 microgram(s)/dose - adrenergics in combination with corticosteroids or other drugs, excl. anticholinergics; formoterol and fluticasone

Ireland - English - HPRA (Health Products Regulatory Authority)

mundipharma pharmaceuticals limited - fluticasone propionate; formoterol fumarate dihydrate - pressurised inhalation, suspension - 250 µg/10 microgram(s)/dose - adrenergics in combination with corticosteroids or other drugs, excl. anticholinergics; formoterol and fluticasone

Ireland - English - HPRA (Health Products Regulatory Authority)

mundipharma pharmaceuticals limited - fluticasone propionate; formoterol fumarate dihydrate - pressurised inhalation, suspension - 50 µg/5 microgram(s)/dose - adrenergics in combination with corticosteroids or other drugs, excl. anticholinergics; formoterol and fluticasone